Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Persantine: Variation in Response Trial
NCT00763009 · UConn Health · PHASE4 · terminated · last registry update 2018-04-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Limited numbers of patients qualified for trial” | – | Registry record, UConn Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC29A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-11Results posted on the registry: Sharon Riddler, Dipyridamole + Placebo, then Dipyridamole (NCT02121756)
- 2018-12-10Results posted on the registry: University of Maryland, Baltimore, Dipyridamole (NCT00349973)
- 2018-09-04Results posted on the registry: Abbott Medical Devices, a drug against SLC29A1 (NCT00465270)
- 2018-08-09Results posted on the registry: W.L.Gore & Associates, Antiplatelet Medical Therapy (NCT00738894)
- 2018-06-11Also stopped (terminated): University of Nottingham, Aspirin, Dipyradimole, Clopidogrel (NCT01661322)
- 2017-11-27Phase 3 first posted: GE Healthcare, PET MPI + SPECT MPI (NCT03354273)
- 2017-09-05Results posted on the registry: University of Pennsylvania, Dipyridamole 200mg and Aspirin 25mg bid: + Dipyridamole 200 mg bid (NCT00906035)
- 2017-09-05Also stopped (terminated): University of Pennsylvania, Dipyridamole 200mg and Aspirin 25mg bid: + Dipyridamole 200 mg bid (NCT00906035)
- 2017-04-24Also stopped (terminated): Ottawa Heart Institute Research Corporation, a drug against SLC29A1 (NCT01520025)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision